Alessandro Poggi
Alessandro Poggi
  • :+39-010-5558367
  • :+39-010-354282

Department of Molecular Oncology
IRCCS AOU San Martino IST-National Institute for Cancer Research


2013 Scientific Abilitation as full professor in Pathology
2013 Scientific Abilitation as full professor in Molecular Oncology
2004 Postdoctoral Degree in Allergology and Clinical Immunology, University of Genoa (50/50 cum laude)
2001 Qualification as a Medical Doctor (94/100)
1993-2000 Medical Doctor and Surgery degree, University of Genoa, Italy (110/110 cum laude).
1983-1987 Postdoctoral Degree in General Pathology, University of Genoa (70/70 cum laude).
1983 Qualification as a Biologist (150/150)
1982 Degree in Biology, University of Genoa, Italy (110/110 cum laude).



Dr Alessandro Poggi has been working on cellular and tumor immunology for more than 25 years. He is authors of 189 original articles published on indexed journals and he is a reviewer of several scientific journals. Starting from his first doctoral degree in Biological Sciences (1982), he worked on functional characteristics of leukocyte subsets. After his Post-Doctoral Fellow training at the Ludwig Cancer Institute in Lausanne, Switzerland (1985-1987), he has been appointed as Assistant Member at the IST (Immunopathology Unit) in Genoa studying natural killer cell development and function, molecular aspects of survival of subsets of leukocytes and the role of mesenchymal stromal and stem cells in tumor microenvironment. In 2000, he has taken his second doctoral degree in Medicine and Surgery and from July 2009, he is director of the Molecular Oncology and Angiogenesis Unit at the IRCCS AOU San Martino IST in Genoa.


Research Interest

Tumor Immunology ,Tumor Microenvironment ,Innate Immunity ,Mesenchymal Stromal cells ,Lymphocyte Activation ,Lymphocyte Regulation ,Immune Escape ,NK cells ,γδ T cells ,NKG2D receptor  NKG2DL ,ADCC ,Tumor Immunotherapy


Professional Activities:

  1. September 1989: Teacher at the Practical Course: “Immunodiagnosis and Immunotherapy of Cancer”, School of Oncology and Biomedical Sciences, Genoa.
  2. November 1989: Teacher at the Practical Course: “Manipulation of immunocompetent cells in oncology”,School of Oncology and Biomedical Sciences, Genoa.
  3. April 1991 and April 1992: Teacher at the Practical Course: “Tecniques of cell culture in immunology”, School of Oncology and Biomedical Sciences, Genoa.November 1993: Teacher at the Practical Course: “Expert in Biotechnology”, School of Oncology and Biomedical Sciences, Genoa. 1991-1993: Teacher of Immunology at the Faculty of Medicine, University of Turin, Italy.
  4. 1990-today: Tutorial for Doctoral and Post Doctoral Students, Faculty of Medicine, Faculty of Biology, School of Biotechnology, Post Doctoral School of Oncology and Post Doctoral School of Clinical Pathology. 2014-2015: Professor of Clinical Immunology, Biomedical Techinician course at University of Genoa



  1. Ghio M., Contini P., Negrini S., Boero S., Musso A., and Poggi A. Soluble HLA-I-mediated secretion of TGF-β1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity. Eur J. Immunol, 2009 Oct 14.
  2. Poggi A., Castellani, S., Musso, A., and Zocchi M.R. Gammadelta T lymphocytes producine IFN-γ and IL-17 in response to Candida albicans or Mycobacterial antigens: possible implications for acute and chronic inflammation.. Curr Med Chem. 2009;16(35):4743-9.
  3. Bruzzone S., Frusciane F., Morando S., Ferrando T., Poggi A., Garuti A., D’Urso A., Selmo M., Soncini D, Benvenuto F., Cea M., Zoppoli G., Moran E., Ballestrero A., Sordat B., Patrone F.,Mostoslavsky R., Uccelli A., and Nencioni A. Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE. PLoS One. 2009 Nov 19;4(11):e7897.
  4. Foresta M., Ropolo M., Degan P., Pettinati I., Kow IW., Damonte G., Poggi A. and Frosina G. Defective Repair of 5-Hydroxy2’deoxycytidine in Cockayne Syndrome Cells and its Complementation by E.coli Formamidopyrimidine DNA Glycosylase and Endonuclease III. Free Radic Biol Med. 2010 Mar 1;48(5):681-
  5. Poggi A., Musso A., Boero S., Canevali P., and Zocchi M.R. Statins as either immunomodulators or anti- cancer drugs: functional activities on tumor stromal cells and natural killer cells. CMCAIAA, 2010, 9,82-92. NI
  6. Poggi A., Prevosto C., Catellani S., Rocco I., Garuti A., and Zocchi M.R. Engagement of CD31 delivers an activating signal that contributes to the survival of chronic lymphocytic leukaemia cells. Br J Haematol. 2010 Nov;151(3):252-64. doi: 10.1111/j.1365-2141.2010.08343.x. Epub 2010 Aug 31
  7. Poggi A., Zancolli M., Catellani S., Boero S., Musso A., and Zocchi MR. Differential survival of γδT cells,
  8. αβT cells, and NK cells upon engagement of NKG2D by NKG2DL-expressing leukemic cells. International Journal of Cancer, 2011 Jul 15;129(2):387-96. doi: 10.1002/ijc.25682. Epub 2010 Nov 3.
  9. Musso A., Zocchi MR., and Poggi. A. Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T cell proliferation and B cell survival. Haematologica, 2011 Jan;96(1):16-23. Epub 2010 Sep 30
  10. Ghio M., Contini P., Negrini S., Mazzei C., Zocchi MR., and Poggi A. Down-regulation of human Natural Killer cell-mediated cytolysis induced by blood transfusion: role of transforming growth factor β1, soluble Fas ligand and soluble class I human leukocyte antigen. Transfusion, 2011 Jul;51(7):1567- 73. doi: 10.1111/j.1537-2995.2010.03000.x. Epub 2011 Jan 7.
  11. Mirabella T., Poggi A., Scaranari M., Mogni M., Lituania M., Baldo C., Cancedda R., Gentili C. Phenotypic characterization of Human Amniotic Fluid Stem Cells (hAFSCs): recruitment of host's progenitor cells after in vivo implantation. Biomaterials 2011 Jun;32(18):4218-27. Epub 2011 Apr 2.
  12. M. Ropolo, E. Cappelli, M. Foresta, A. Poggi, L. Proietti-De-Santis and G. Frosina. Detective resolution of pH2AX foci and enhanced DNA breackage in ionizing radiation-treated Cockayne syndrome B cells. IUBMB Life, 2011 Apr;63(4):272-6. doi: 10.1002/iub.445. Epub 2011 Mar 24
  13. S. Catellani, I. Pierri, M. Gobbi, A. Poggi and M.R. Zocchi. Imatinib mesylate treatment increases CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in the bone marrow of patients with chronic myelogenous leukemia. PLoS One. 2011 Apr 18;6(4):e18925.
  14. Fenoglio D, Zocchi MR, Parodi A, Durando P, Gabutitp G, Gasparini R, Poggi A. MF-59 adjuvant influence on the functions of gammadelta T cells in HIV-1+ adults immunized with influenza seasonal vaccine. J Prev Med Hyg. 2011 Sep;52(3):137-41.
  15. MR Zocchi, S. Catellani, P. Canevali, S. Tavella, A. Garuti, B. Villaggio, A. Zunino, M. Gobbi6, Giulio Fraternali-Orcioni, Annalisa Kunkl, Jean-Louis Ravetti, Silvia Boero, Alessandra Musso, and Alessandro Poggi. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D-Ligands recognition in Hodgkin lymphomas. Blood, 2011 Dec 13.
  16. A. Poggi and M.R. Zocchi Modulating mesenchymal stromal cell function with cholesterol synthesis inhibitors. CMC (Current Medicinal Chemistry). Curr Med Chem. 2011;18(34):5196-205.
  17. Zocchi MR, Poggi A.Targeting the microenvironment in hematological malignancies: how to condition both stromal and effector cells to overcome cancer spreading. Curr Med Chem. 2011;18(34):5172-3.
  18. A. Poggi, P. Canevali, M. Contatore, and G. Ciprandi. Higher frequencies of CD161+ circulating T lymphocytes in allergic rhinitis patients than in healthy donors. International Archives of Allergy and Immunology, Int Arch Allergy Immunol. 2012 Jan 25;158(2):151-156.
  19. A. Raso, D. Vecchio, E. Cappelli, M. Ropolo, A. Poggi, P. Nozza, R. Biassoni, S. Mascelli, V. Capra, F. Kalfas, P. Severi, and G. Frosina. Characterization of glioma stem cells through multiple stem cell markers and their specific sensitization to double strand breaks-inducing agents by pharmacological inhibition of Ataxia Telangiectasia Mutated protein. Brain Pathology, Brain Pathol. 2012 Jan 18. doi: 10.1111/j.1750- 3639.2012.00566.
  20. Colombo BM, Canevali P, Magnani O, Rossi E, Puppo F, Zocchi MR, Poggi A. Defective expression and function of the leukocyte associated Ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients. PLoS One. 2012;7(2):e31903. Epub 2012 Feb 15.
  21. E. Boggio; M. Melensi; S. Bocca; A. Chiocchetti; C. Comi; N. Clemente; E. Orilieri; M. F. Soluri; S. D'Alfonso; R. Mechelli; G. Gentile; A. Poggi; M. Salvetti; U. Ramenghi and U. Dianzani. The -346T Polymorphism of the SH2D1A gene is associated with development of autoimmunity/lymphoproliferation in males with defective Fas function. Hum Immunol. 2012 May;73(5):585-92. doi: 10.1016/j.humimm.2012.02.025. Epub 2012 Mar 7
  22. F. Montecucco, I. Bauer, V. Braunersreuther, S. Bruzzone, A. Poggi, E. Mannino, G. Pelli, K. Galan, M. Bertolotto, S. Lenglet, C. Montessuit, R. Lerch, C. Pellieux, A. Garuti, F. Dallegri, R. Mostoslavsky, F. Patrone, F. Mach, A. Nencioni. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (Nampt) reduces neutrophil-mediated injury in a mouse model of myocardial ischemia/reperfusion (I/R).
  23. Antioxid Redox Signal. 2013 Feb 20;18(6):630-41. doi: 10.1089/ars.2011.4487. Epub 2012 May 14.Magnone M, Bauer I, Poggi A, Mannino E, Sturla L, Brini M, Zocchi E, De Flora A, Nencioni A, Bruzzone S. NAD+ levels control Ca2+ stores replenishment and mitogen-induced increase of cytosolic Ca2+ by ADPR-dependent TRPM2 gating in human T lymphocytes. J Biol Chem. 2012 Jun 15;287(25):21067-81. doi: 10.1074/jbc.M111.324269. Epub 2012 Apr 30
  24. Poggi A, Zocchi MR.Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment.Oncoimmunology. 2012 Mar 1;1(2):214-216.
  25. Bauer I, Grozio A, Lasigliè D, Basile G, Sturla L, Magnone M, Sociali G, Soncini D, Caffa I, Poggi A, Zoppoli G, Cea M, Feldmann G, Mostoslavsky R, Ballestrero A, Patrone F, Bruzzone S, Nencioni A.The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses.J Biol Chem. 2012 Nov 30;287(49):40924-37. doi: 10.1074/jbc.M112.405837. Epub 2012 Oct 18.
  26. Penna I, Vassallo I, Nizzari M, Russo D, Costa D, Menichini P, Poggi A, Russo C, Dieci G, Florio T, Cancedda R, Pagano A. A novel snRNA-like transcript affects amyloidogenesis and cell cycle progression through perturbation of Fe65L1 (APBB2) alternative splicing. Biochim Biophys Acta. 2013 Jun;1833(6):1511-
  27. Laurent S, Queirolo P, Boero S, Salvi S, Piccioli P, Boccardo S, Minghelli S, Morabito A, Fontana V, Pietra G, Carrega P, Ferrari N, Tosetti F, Chang LJ, Mingari MC, Ferlazzo G, Poggi A, Pistillo MP. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production. J Transl Med. 2013 May 1;11(1):108. [Epub ahead of print].
  28. Poggi A, Boero S, Musso A, Zocchi MR. Selective role of mevalonate pathway in regulating perforin but not FasL and TNFα release in human natural killer cells. PLoS One. 2013 May 7;8(5):e62932. doi:
  29. Amaro A, Mirisola V, Angelini G, Musso A, Tosetti F, Esposito AI, Perri P, Lanza F, Nasciuti F, Mosci C, Puzone R, Salvi S, Truini M, Poggi A, Pfeffer U. Evidence of EGFR Signaling in Uveal Melanoma, Its inhition by Gefitinib and Cetuximab Mediated Antibody-Dependent Cellular Cytotoxicity. Eur J Cancer. 2013 Jul 9. doi:pii: S0959-8049(13)00486-3. 10.1016/j.ejca.2013.06.011. [Epub ahead of print]
  30. Poggi A and Zocchi MR. Stress immunity in lymphomas: mesenchymal cells as a target of therapy.Front Biosci (Landmark Ed). 2014 Jan 1;19:281-90
  31. Musso A., Catellani S., Canevali P.,Tavella S., Venè R., Boero S., Pierri I., Gobbi M., Kunkl A., Ravetti J-L, Zocchi MR. and Poggi A. Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vdelta 2 T lymphocytes in non-Hodgkin lymphomas. Haematologica/the Hematology Journal, 2014 Jan;99(1):131-9. doi: 10.3324/haematol.2013.097311. Epub 2013 Oct 25
  32. Scabini S, Montecucco F, Nencioni A, Zoppoli G, Sartini M, Rimini E, Massobrio A, De Marini L, Poggi A, Boaretto R, Romairone E, Ballestrero A, Ferrando V. The effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer. World J Surg Oncol. 2013 Nov 18;11:292. doi: 10.1186/1477- 7819-11-292. 24246069.
  33. Vecchio D, Daga A, Carra E, Marubbi D, Baio G, Neumaier CE, Vagge S, Corvò R, Pia Brisigotti M, Louis Ravetti J, Zunino A, Poggi A, Mascelli S, Raso A, Frosina G. Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019. Int J Cancer. 2013 Dec 19. doi: 10.1002/ijc.28680. [Epub ahead of print] in the press.
  34. Giuliani M, Poggi A, Bennaceur Griscelli A, and Lataillade JJ. IFNGamma Priming Protects Fetal and Embryonic MSC from NK Cell-Mediated Killing and Improves their Immunosuppressive Properties: Role of Activating and Inhibitory Receptors. J Cell Sci Ther 2014, 5:3
  35. Poggi A, and ZocchiMR. NK cell autoreactivity and autoimmune diseases. Front Immunol. 2014 Feb 4;5:27. doi: 10.3389/fimmu.2014.00027. eCollection 2014. Review
  36. Poggi A, Zocchi MR. How to exploit stress-related immunity against Hodgkin's lymphoma: Targeting ERp5 and ADAM sheddases. Oncoimmunology. 2013 Dec 1;2(12):e27089. Epub 2013 Dec 5. Review.
  37. Foresta M, Izzotti A, La Maestra S, Micale R, Poggi A, Vecchio D, Frosina G. Accelerated Repair and Reduced Mutagenicity of DNA Damage Induced by Cigarette Smoke in Human Bronchial Cells Transfected with E.coli Formamidopyrimidine DNA Glycosylase. PLoS One. 2014 Jan 31;9(1):e87984. doi: 10.1371/journal.pone.0087984. eCollection 2014.
  38. Poggi A, Musso A, Dapino I, Zocchi MR. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. Immunol Lett. 2014 May-Jun;159(1-2):55-72. doi: 10.1016/j.imlet.2014.03.001. Epub 2014 Mar 20.
  39. Venè R, Cardinali B, Arena G, Ferrari N, Benelli R, Minghelli S, Poggi A, Noonan DM, Albini A, Tosetti F. Glycogen Synthase Kinase 3 Regulates Cell Death and Survival Signaling in Tumor Cells under Redox Stress. Neoplasia. 2014 Sep;16(9):710-22. doi: 10.1016/j.neo.2014.07.012.
  40. Soncini D, Caffa I, Zoppoli G, Cea M, Cagnetta A, Passalacqua M, Mastracci L, Boero S, Montecucco F, Sociali G, Lasigliè D, Damonte P, Grozio A, Mannino E, Poggi A, D'Agostino VG, Monacelli F, Provenzani A, Odetti P, Ballestrero A, Bruzzone S, Nencioni A.Nicotinamide Phosphoribosyltransferase Promotes Epithelial-to-Mesenchymal Transition as a Soluble Factor Independent of Its Enzymatic Activity. J Biol Chem. 2014 Dec 5;289(49):34189-204. doi: 10.1074/jbc.M114.594721. Epub 2014 Oct 20
  41. Poggi A, Zocchi MR. γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy.Front Immunol. 2014 Nov 11;5:575. NI
  42. Poggi A, Zocchi MR. Mesenchymal stromal cells as regulators of anti-tumour immune response. Indian J Med Res. 2015 Feb;141(2):139-42
  43. Montecucco F, Lenglet S, Carbone F, Boero S, Pelli G, Burger F, Roth A, Bertolotto M, Nencioni A, Cea M, Dallegri F, Fraga-Silva RA, Fougère L, Elfakir C, Gassner AL, Rudaz S, Parissaux X, Wils D, Salomé M, Vuilleumier N, Poggi A, Mach F. Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. Vascul Pharmacol. 2015 Apr 25.
  44. Venè R, Tosetti F, Minghelli S, Poggi A, Ferrari N, Benelli R. Celecoxib increases EGF signaling in colon tumor associated fibroblasts, modulating EGFR expression and degradation.Oncotarget. 2015 May20;6(14):12310-25.


Autoimmune Journal Flyer